Case reports of evaluation and desensitization for anti-thymocyte globulin hypersensitivity

Area of Science:

• Immunology
• Transplantation Medicine
• Allergy and Clinical Immunology

Background:

• Biologic products from heterologous sera, such as anti-thymocyte globulin (ATG), are used for conditions like renal transplantation and aplastic anemia.
• ATG, being a heterologous serum product, carries a risk of adverse reactions, including anaphylaxis.
• Pre-administration skin testing is a method to assess patient hypersensitivity to ATG.

Observation:

• This report details four patients undergoing ATG administration, focusing on the evaluation of hypersensitivity through skin testing and subsequent reactions.
• The study also examines desensitization procedures in patients with confirmed ATG hypersensitivity who required the medication.
• None of the patients successfully completed the ATG desensitization protocol, highlighting challenges in the procedure.

Findings:

• Skin testing for ATG hypersensitivity can present challenges in accurate interpretation and patient response evaluation.
• ATG desensitization protocols are associated with complications and difficulties, even when essential for patient treatment.
• Successful desensitization to ATG, a xenogeneic protein, is not guaranteed and requires specialized medical expertise.

Implications:

• Physicians must be adept at interpreting skin tests for ATG hypersensitivity.
• Careful consideration of risks versus benefits is crucial when administering ATG to hypersensitive patients.
• Management of ATG desensitization requires familiarity with potential complications and procedural difficulties.